Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

NSAID RCT for Prevention of Altitude Sickness

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
Statusas
Rėmėjai
Naval Health Research Center
Bendradarbiai
University of California, San Diego

Raktažodžiai

Santrauka

The proposed study is a prospective, randomized, double-blind, placebo-controlled clinical trial evaluating ibuprofen and placebo for the prevention of neurological forms of altitude illness [including high altitude headache (HAH), acute mountain sickness (AMS), high altitude cerebral edema (HACE), and an emerging concept of High Altitude Anxiety]. The study will take place in the spring and summer of 2012 at the Marine Corps Mountain Warfare Training Center in the Eastern Sierras near Bridgeport, California. US Marines from near sea level will participate in battalion-level training exercises at between 8,500-11,500 Feet, where some altitude illness is expected. Concurrent measures used to determine objective markers of altitude illness, such that validated clinical scales, rapid cognitive screening tests, will inform us of symptoms of altitude illness.

Datos

Paskutinį kartą patikrinta: 04/30/2012
Pirmasis pateikimas: 04/12/2012
Numatytas registravimas pateiktas: 05/22/2012
Pirmas paskelbtas: 05/24/2012
Paskutinis atnaujinimas pateiktas: 05/22/2012
Paskutinis atnaujinimas paskelbtas: 05/24/2012
Faktinė studijų pradžios data: 06/30/2012
Numatoma pirminio užbaigimo data: 09/30/2012
Numatoma studijų užbaigimo data: 09/30/2012

Būklė ar liga

Spectrum of Altitude-associated Neurologic Forms of Altitude

Intervencija / gydymas

Drug: Ibuprofen 600mg orally three times daily

Fazė

Fazė 2

Rankų grupės

RankaIntervencija / gydymas
Experimental: Ibuprofen
Ibuprofen 600mg taken three times daily for four days.
Placebo Comparator: placebo
Avicel placebo capsules three times daily for four days

Tinkamumo kriterijai

Amžius, tinkami studijuoti 18 Years Į 18 Years
Tinkamos studijoms lytysAll
Priima sveikus savanoriusTaip
Kriterijai

INCLUSION CRITERIA:

Active duty military

Current in their medical screening

EXCLUSION CRITERIA:

Upper respiratory tract infection or influenza

Have had a reaction to Ibuprofen, aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Stayed the night at an altitude of greater than 6,700 feet within the last 7 days

Headache at baseline

Have altitude sickness or more than one mild symptom of any severity on the Lake Louise Questionnaire including headache, poor appetite, nausea, vomiting, fatigue, weakness, dizziness, and/or poor sleep (insomnia)

Low blood oxygen or low oxygen saturation (<90%)

Pregnant or cannot exclude the possibility of being pregnant, or have missed menses by over 7 days.

Have taken any of the following in 48 hours preceding enrollment: acetazolamide/Diamox, steroids (dexamethasone/Decadron, prednisone), theophylline, or diuretics such as Lasix

Have taken any of the following within 12 hours preceding enrollment: Ibuprofen/Motrin, Naprosyn/Naproxen/Aleve, aspirin, or Acetaminophen/Tylenol.

Have taken any other medication that may be known to have potential for drug-drug interactions with ibuprofen, including (but not limited to): ACE-inhibitor antihypertiensives, thiazide diuretics, furosemide, lithium, methotrexate, and H-2 Agonists.

Have any medical conditions which may make participation hazardous (*by self-report which can be clarified before enrollment with the study physicians as necessary), including:

- Heart disease - Congestive heart failure, heart attack in the last month or severe coronary artery disease, or significant heart valve problems or other congenital problems.

- Lung disease - Restrictive lung disease, chronic obstructive pulmonary disease (COPD), severe obstructive sleep apnea, or pulmonary hypertension of any cause.

- Neurological disorders - Hydrocephalus, history of brain tumor, history of severe brain trauma or coma, pseudotumor cerebri, or severe uncontrolled headaches/migraine disorder (as diagnosed by a doctor).

- Gastrointestinal - Known stomach ulcer or history of gastrointestinal bleeding.

- Blood disorders - Anemia, leukemia, or other coagulopathies of any kind.

- Kidney disease - Kidney failure or other known kidney disease.

General - The Principal Investigator and co-investigator reserve the right to exclude a potential participant with conditions that in their judgment are not listed above, but which would reasonably represent concern for the participant's health and welfare, including (but not limited to) conditions that may directly antagonize mechanisms of acclimatization to altitude, organ failure, metastatic/malignant neoplasm, space-occupying brain lesions or diagnoses typically known to raise intracranial pressure, and disorders that are likely to antagonize adequate respiration, blood oxygenation, and/or circulation.

Rezultatas

Pirminės rezultatų priemonės

1. Change in the incidence of AMS as measured on the Lake Louise AMS Questionnaire across the study. [Twice daily]

The measure is assessed twice daily for four days

Antrinės rezultatų priemonės

1. 1. Change in High Altitude Headache measured by the Visual Analog Scale (VAS) across the study. [Twice daily]

The measure is assessed twice daily for four days

2. 2. Change in cognitive performance as measured by King-Devick across the study. [Twice daily]

The measure is assessed twice daily for four days

3. 3. Change in the presence of anxiety and somatic symptoms using the BSI-12 screening tool across the study [Twice daily]

The measure is assessed twice daily for four days

4. 4. Change in the oxygen concentration using Pulse Oximetry across the study. [Twice daily]

The measure is assessed twice daily for four days

5. 5. Change in hydration status as measured by urine specific gravity across the study. [Twice daily]

The measure is assessed twice daily for four days

6. 6. Change in HAH incidence and severity as measured on the Lake Louise AMS Questionnaire across the study. [Twice daily]

The measure is assessed daily for four days

7. 7. Change in cognitive performance as measured by the Quickstick across the study [Twice daily]

The measure is assessed twice daily for four days

8. 8. Change in the presence of anxiety and somatic symptoms using the GAD-2 screening tool across the study [Twice daily]

The measure is assesed twice daily for four days

9. 9. Incidence of severe AMS as measured by a score of 6 or greater on the Lake Louise AMS Questionnaire. [Twice Daily]

The measure is assessed twice daily for four days

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge